Notable Movers: Ligand Pharmaceuticals Inc., Telik, Inc., Hanger Inc., Hemispherx BioPharma, Inc

Lakeway, NY -- (SBWIRE) -- 02/15/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) went up 6.36% and closed at $22.07. The Company released fourth quarter results. Total revenues from continuing operations for the fourth quarter of 2012 were $13.6 million compared to $12.9 million for the fourth quarter of 2011. Net income for the fourth quarter of 2012 was $1.1 million or $0.05 per share compared to net income of $4.7 million,\ or $0.24 per share in the fourth quarter of 2011.

Is LGND a Strong At New highs? Let’s Find out Here

Telik, Inc. (NASDAQ:TELK) soared 6.17% and closed at $1.72. In the last one year, the stock is down over 68%. The 52-week range for the stock is $1.09 and $7.34. Telik is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company’s drug discovery technology, Target-Related Affinity Profiling.

Is TELK a Strong Buying Opportunity After The Recent Slump? Find out Here

Hanger Inc. (NYSE:HGR) soared 6.16% and closed at $30.84. The Company announced fourth quarter results. The net sales increased 9.7% to $272.2 million. Diluted earnings per share were $0.62 for the fourth quarter of 2012 compared to $0.52 for the same period of 2011. The Company’s cash flow from operations increased $19.5 million to $81.3 million for the year ended December 31, 2012 compared to $61.8 million for 2011.

Is HGR a Strong At New highs? Let’s Find out Here

Hemispherx BioPharma, Inc. (NYSE:HEB) closed at $0.24 on a traded volume of 616k shares. Hemispherx Biopharma, Inc. is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Is HEB a Strong Buying Opportunity After The Recent Slump? Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.